Impact of methotrexate dose on efficacy of adalimumab in Japanese patients with rheumatoid arthritis: Results from registered data analyses

Modern Rheumatology

Volumn 27, Issue 1, 2017, Pages 15-21

  Nakashima, Yasuharu ^a   Miyahara, Hisaaki ^b   Kondo, Masakazu ^c   Fukuda, Takaaki ^d   Harada, Hiroshi ^e   Haraguchi, Akihisa ^a   Inoue, Yasushi ^f   Ishinishi, Takashi ^g   Maekawa, Masayuki ^h   Maeyama, Akira ⁱ   Nakashima, Munetoshi ^d   Shono, Eisuke ^j   Suematsu, Eiichi ^b   Shimauchi, Takashi ^k   Tsuru, Tomomi ^l   Tsukamoto, Hiroshi ^a   Yoshizawa, Shigeru ^m   Yoshizawa, Seiji ⁿ   Iwamoto, Yukihide ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^c Kondo Clinic of Rheumatology and Orthopaedic Surgery   (Japan)

^d KURUME UNIVERSITY MEDICAL CENTER   (Japan)

^e Morooka Orthopedic Clinic   (Japan)

^f FUKUOKA RED CROSS HOSPITAL   (Japan)

^g Ishinishi Orthopaedic Clinic   (Japan)

^h Maekawa Orthopedics   (Japan)

ⁱ FUKUOKA UNIVERSITY   (Japan)

^j Shono Rheumatology Clinic   (Japan)

^k Fukuoka Hoeikai Hospital   (Japan)

^l PS Clinic   (Japan)

^m FUKUOKA NATIONAL HOSPITAL   (Japan)

ⁿ HAMANOMACHI HOSPITAL   (Japan)

more..

Author keywords

Adalimumab; Clinical practice; Methotrexate; Remission; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; METHOTREXATE; PREDNISOLONE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; DISEASE ACTIVITY SCORE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; INFECTIOUS PNEUMONIA; INTERSTITIAL PNEUMONIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLEURA FLUID; PRIORITY JOURNAL; RASH; REMISSION; RHEUMATOID ARTHRITIS; SINUSITIS; AGED; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG MONITORING; DRUG POTENTIATION; JAPAN; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADALIMUMAB; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JAPAN; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84965047539     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2016.1170958     Document Type: Article

References (24)

1. Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Den Broeder AA, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice:a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis. 2012;71:845–50.
2. Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, et al. Evidence for treating rheumatoid arthritis to target:results of a systematic literature search update. Ann Rheum Dis. 2016;75(1):16–22
3. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target:recommendations of an international task force. Ann Rheum Dis. 2010;69:631–7.
4. Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying anti-rheumatic drugs:a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010;69:976–86.
5. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate:the ARMADA trial. Arthritis Rheum. 2003;48:35–45.
6. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study:a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37.
7. Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, et al. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis:the HOPEFUL 1 study. Ann Rheum Dis. 2014;73:536–43.
8. Takeuchi T, Tanaka Y, Kaneko Y, Tanaka E, Hirata S, Kurasawa T, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis:retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumatol. 2012;22:327–38.
9. Smolen JS, van der Heijde DM, Keystone EC, van Vollenhoven RF, Goldring MB, Guérette B, et al. Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis:protection beyond disease control by adalimumab plus methotrexate. Ann Rheum Dis. 2013;72:1156–62.
10. Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients:postmarketing surveillance report of 7740 patients. Mod Rheumatol. 2014;24:390–8.
11. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305:1460–8.
12. Yazici Y, Sokka T, Kautiainen H, Swearingen C, Kulman I, Pincus T., Long term safety of methotrexate in routine clinical care:discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis. 2005;64:207–11.
13. The Japan College of Rheumatology and the Institute of Data Analysis. Study of efficacy and safety of methotrexate at more than 8 mg/week:evaluation of 3 RA patients cohorts (IORRA, REAL and NinJa) (in Japanese). Available from:http://www.ryumachi-jp.com/pdf/MTXHighdose.pdf [last accessed 15 Dec 2015].
14. Oh K, Ito S, Unno M, Kobayashi D, Azuma C, Abe A, et al. The rate of decrease in the disease activity of rheumatoid arthritis during treatment with adalimumab depends on the dose of methotrexate. Intern Med. 2015;54:1035–41.
15. Nakashima Y, Kondo M, Harada H, Horiuchi T, Ishinishi T, Jojima H, et al. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics:tocilizumab in combination with methotrexate. Mod Rheumatol. 2010;20:343–52.
16. Nakashima Y, Kondo M, Fukuda T, Harada H, Horiuchi T, Ishinishi T, et al. Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice:results from 3 years of prospectively registered data. Mod Rheumatol. 2014;24:258–64.
17. Steinbrocker O, Traeger CH, Batterman RC., Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc. 1949;140:659–662.
18. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL., Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39:34–40.
19. van Riel PL, van Gestel AM, van de Putte LB., Development and validation of response criteria in rheumatoid arthritis:steps towards an international consensus on prognostic markers. Br J Rheumatol. 1996;35(Suppl. 2):4–7.
20. Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, et al. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry:an appraisal of predictors. J Rheumatol. 2012;39:1179–84.
21. Burmester GR, Kivitz AJ, Kupper H, Arulmani U, Florentinus S, Goss SL, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab:the randomized CONCERTO trial. Ann Rheum Dis. 2015;74:1037–44.
22. Krieckaert CL, Nurmohamed MT, Wolbink GJ., Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71:1914–15.
23. Miyasaka N, The CHANGE study investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation:the CHANGE study. Mod Rheumatol. 2008;18:252–62.
24. Schiff MH, Jaffe JS, Freundlich B., Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis:drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014;73:1549–51.